Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Deepening of response through salvage therapy not linked to improved progression-free, overall survival.
The scoring system could be incorporated into future trials in elderly patients, authors said.
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
Responses were seen in patients who have few remaining treatment options.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally is linked to higher satisfaction.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
For patients receiving drug therapy, economic burden substantial across lines of therapy.
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
Elderly patients with myeloma who switched to bortezomib, thalidomide, and dexamethasone during frontline chemotherapy had better survival outcomes.
A retrospective analysis of myeloma patients with extramedullary disease provided insights into the characteristics that may influence outcomes.
Patients with lymphoma or myeloma were assessed prior to and 1 month after initiating chemotherapy for depressive symptoms.